HSPA9 and cholangiocarcinoma: High expression of mortalin has earlier been shown to be consistently associated with poor prognosis and survival in malignancies such as breast, brain, cholangiocarcinoma, colon, gastric, hepatocellular, lung, pancreatic, prostate, and thyroid cancers [14,24,25,28,29,30,31,32,33].